Investing: La FDA otorga estatus RMAT a la terapia para linfoma de Lyell
La FDA otorga estatus RMAT a la terapia para linfoma de Lyell
Seeking Alpha: Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
Seeking Alpha: Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the ...
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell ...
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the ...
Nasdaq: Lyell Immunopharma Accelerates Development of IMPT-314 for Large B-Cell Lymphoma, Discontinues LYL119 Program to Focus Resources
Lyell Immunopharma, Inc. has announced plans to accelerate the development of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell therapy for aggressive large B-cell lymphoma, with pivotal trials expected ...
Lyell Immunopharma Accelerates Development of IMPT-314 for Large B-Cell Lymphoma, Discontinues LYL119 Program to Focus Resources
Lyell Immunopharma, Inc., a clinical-stage company focused on next-generation CAR T-cell therapies, announced key executive appointments to enhance its leadership team and clinical capabilities. Mark ...
Learn about Lyell and how we are building an industry-leading clinical-stage pipeline of CAR-T cell product candidates for cancer.